However, recent studies with KRAS mutant-specific inhibitors note similar TME changes suggesting that the majority of effects observed with our pan KRAS inhibitors are likely driven by on-target tumor cell-intrinsic effects (55). The gene discussed is KRAS; the disease is neoplasm.